In-Hospital Left Ventricular Assist Devices Deactivation and Death Experience: A Single-Institution Retrospective Analysis
- 18 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (11) , 1339-1345
Abstract
Best practices for left ventricular assist devices (LVADs) deactivation at end-of-life (EOL) have yet to be elucidated. We conducted a single-institution retrospective review of patients who died following LVAD deactivation between January 2017 and March 2020. Data were obtained from institutional databases and electronic health record and were analyzed using descriptive statistics. Fifty-eight patients (70% male, 70% African American, median age 62 years) were categorized by implant strategy: bridge therapy (BT, N = 22, 38%) or destination therapy (DT, N = 36, 62%). Clinical events leading to deactivation were categorized either acute (e.g., stroke [N = 31, 53%]), gradual decline (N = 12, 21%), or complications during index hospitalization (N = 15, 26%). Implant strategy was not associated with clinical trajectory leading to EOL (p = 0.67), hospital unit of death (p = 0.13), or use of mechanical ventilation (p = 0.69) or renal replacement therapy (p = 0.81) during terminal hospitalization. Overall time from admission to code status change was mean 27.0 days (SD 30.3 days). Compared with BT patients, DT experienced earlier do-not-resuscitate (DNR) orders (p ≤ 0.01) and shorter survival post-deactivation (p ≤ 0.01). Deactivations after gradual decline tended to occur outside ICUs, compared with acute events or index implant-related complications (p = 0.04). Implant strategy was not associated with differences in EOL experience except regarding timing of DNR order and survival post-deactivation.Keywords
This publication has 17 references indexed in Scilit:
- Clinical Outcomes After Continuous-Flow Left Ventricular Assist DeviceCirculation: Heart Failure, 2014
- Palliative Medicine Consultation for Preparedness Planning in Patients Receiving Left Ventricular Assist Devices as Destination TherapyMayo Clinic Proceedings, 2011
- End-of-life decision making and implementation in recipients of a destination left ventricular assist deviceThe Journal of Heart and Lung Transplantation, 2010
- Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure PatientsJACC, 2010
- Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist DeviceNew England Journal of Medicine, 2009
- Understanding their Options: Determinants of Hospice Discussion for Older Persons with Advanced IllnessJournal of General Internal Medicine, 2009
- Ethical challenges with the left ventricular assist device as a destination therapyPhilosophy, Ethics, and Humanities in Medicine, 2008
- Physician Attitudes Toward End-Stage Heart Failure: A National SurveyThe American Journal of Medicine, 2008
- Use of a Continuous-Flow Device in Patients Awaiting Heart TransplantationNew England Journal of Medicine, 2007
- Trajectory of End-Stage Heart Failure: The Influence of Technology and Implications for Policy ChangePerspectives in Biology and Medicine, 2006